Tag Archives: health

#BIO 2013: Open Innovation and Biopharmaceutical R&D

Menelas Pangalos

In these changing times, the concept of Open Innovation is one that we at AstraZeneca have fully embraced. By sharing new ideas and enabling scientific innovation to cross boundaries between companies, academia, government and non-profit organizations, we can accelerate new ideas into innovative medicines. An Open Innovation discussion at BIO I will discuss the importance that AstraZeneca places on Open Innovation today at this year’s BIO International Convention. An interactive session will include a panel discussion and presentations Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

Q & A with Eli Lilly’s Eric Siemers

Q+A with Eli Lillys Eric Siemers

In October 2012, Eli Lilly and Company released results of its Expedition trials, two Phase 3, double-blind, placebo-controlled studies of the anti-amyloid antibody solanezumab, in patients with mild-to-moderate Alzheimer’s disease. Although cognitive decline was slowed in patients with early stage disease in one trial, and there were also positive signs from the other trial, those findings were not statistically significant. But a secondary analysis conducted independently by a panel of academic researchers pooled data from Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , ,

New Challenges in the Fast Changing Landscape of Bioinformatics

Adina

The world of DNA sequencing and bioinformatics has evolved at a staggering pace. In 2009, the biggest problem for researchers was creating an efficient solution for sequencing DNA. At that time, sequencing cost of $100,000 for a single human and took 30 days of chemical processing to produce the raw sequencing output. In four years, DNA sequencing technology has advanced rapidly, outpacing even Moore’s Law. Today, researchers can sequence a whole human genome for about Read More >

Health  |  2 Comments  |  Email This Post
Tags: , , , , , , , , ,

Worldwide Orphan Drug Market to Grow to $127 Billion by 2018

Infographic

The 2013 Orphan Drug Report from Evaluate, which launched today at the 2013 BIO international Convention, sheds light on the market dynamics of orphan drugs — pharmaceutical products aimed at rare diseases or disorders — projecting that sales will experience a compound annual growth rate of 7.4 percent between 2012 and 2018, nearly double that of the prescription drug market, excluding generics.  The report based on EvaluatePharma® data found that the worldwide orphan drug market Read More >

Health  |  Leave a comment  |  Email This Post
Tags: , , , , , ,

Expanding Access to Orphan Drugs

Orphan Drugs

At present many orphan diseases do not have any licensed treatments, and for those conditions where there is a therapy, it is often the only therapy in the class that is available. However, this is not always the case. In the field of blood-plasma proteins, therapies to treat hemophilia, alpha-1 deficiency and primary immune deficiencies have multiple innovator versions in a therapeutic class. Often one product in the class has received an orphan designation and Read More >

Events  |  Leave a comment  |  Email This Post
Tags: , , , , , ,